Flerie AB and Lipum AB have announced their planned merger, with Flerie absorbing Lipum, aiming to enhance funding and accelerate the development of innovative treatments for chronic inflammatory diseases.

Target Information

Flerie AB (publ) and Lipum AB (publ), referred to as "the Companies", announced on November 18, 2025, that their boards have approved a merger plan to combine Flerie and Lipum through a legal merger. This merger will result in Lipum being absorbed by Flerie, with Lipum's operations being incorporated into a new subsidiary under Flerie's wholly owned subsidiary, Flerie Invest AB. The merger is contingent on approvals from extraordinary general meetings of both Companies. Notable shareholders representing approximately 16.52% of Lipum's shares have committed to support the merger.

The merger values Lipum at approximately 338.1 million SEK, offering a premium of about 40% per share based on Lipum's average trading price on Nasdaq First North Growth Market over the last ten trading days.

Industry Overview in Sweden

Sweden is a recognized leader in the biopharmaceutical sector, particularly in the development of innovative treatments for chronic diseases. The country has established a robust life sciences ecosystem, featuring collabo